Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer

Cell Cycle

Volumn 9, Issue 10, 2010, Pages 1918-1928

  Caldon, C Elizabeth ^a   Sutherland, Robert L ^a,b   Musgrove, Elizabeth A ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Alveologenesis; Breast cancer; Cell cycle; Cyclin D1; Differentiation; Mammary gland; Proliferation; Rb

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; BETA CASEIN; CAVEOLIN 1; CELL CYCLE PROTEIN; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; GLUCOCORTICOID; HELIX LOOP HELIX PROTEIN; HISTONE DEACETYLASE INHIBITOR; MELATONIN; MUTANT PROTEIN; P21 ACTIVATED KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN P21; PROTEIN P27; PROTEIN P57; RETINOBLASTOMA PROTEIN; RETINOIC ACID; VITAMIN D;

ADIPOCYTE; APOPTOSIS; BREAST CANCER; BREAST EPITHELIUM; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CELL PROLIFERATION; DRUG TARGETING; EPITHELIUM CELL; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH;

EID: 77953626325     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.10.11474     Document Type: Review

References (155)

1. Satyanarayana A, Kaldis P. Mammalian cell cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009.
2. Coqueret O. New roles for p21 and p27 cell cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003; 13:65-70.
3. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms and consequences. Cancer Res 2005; 65:3980-5.
4. Kip1 and its alterations in tumor cells: a review. J Cell Physiol 2000; 183:18-27.
5. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004; 145:5439-47.
6. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000; 16:145-71.
7. Iavarone A, King ER, Dai X-M, Leone G, Richard Stanley E, Lasorella A. Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages. Nature 2004; 432:1040-5.
8. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995; 9:2364-72.
9. 27Kip1-deficient mice. Cell 1996; 85:733-44.
10. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003; 114:323-34.
11. Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 1998; 280:1069-72.
12. Waf1/Cip1 suppresses keratinocyte differentiation independently of the cell cycle through transcriptional upregulation of the IGF-I gene. J Biol Chem 2006; 281:30463-70.
13. Sumrejkanchanakij P, Eto K, Ikeda M-A. Cytoplasmic sequestration of cyclin D1 associated with cell cycle withdrawal of neuroblastoma cells. Biochem Biophys Res Commun 2006; 340:302-8.
14. Tamamori-Adachi M, Ito H, Sumrejkanchanakij P, Adachi S, Hiroe M, Shimizu M, et al. Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation. Circul Res 2003; 92:12-9.
15. Kip1. Cell Growth Differ 1998; 9:595-610.
16. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, et al. Cyclin D1 repression of Peroxisome Proliferator-Activated Receptor γ expression and transactivation. Mol Cell Biol 2003; 23:6159-73.
17. Fu M, Rao M, Bouras T, Wang C, Wu K, Zhang X, et al. Cyclin D1 inhibits peroxisome proliferator-activated receptor γ-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem 2005; 280:16934-41.
18. Fajas L, Landsberg RL, Huss-Garcia Y, Sardet C, Lees JA, Auwerx J. E2Fs regulate adipocyte differentiation. Dev Cell 2002; 3:39-49.
19. Abella A, Dubus P, Malumbres M, Rane SG, Kiyokawa H, Sicard A, et al. Cdk4 promotes adipogenesis through PPARγ activation. Cell Metabolism 2005; 2:239-49.
20. 1 cyclin-dependent kinases. J Biol Chem 2001; 276:8524-34.
21. Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 1995; 267:1022-4.
22. Rao SS, Chu C, Kohtz DS. Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol Cell Biol 1994; 14:5259-67.
23. Ratineau C, Petry MW, Mutoh H, Leiter AB. Cyclin D1 represses the basic helix-loop-helix transcription factor, BETA2/NeuroD. J Biol Chem 2002; 277:8847-53.
24. Fu M, Wang C, Rao M, Wu X, Bouras T, Zhang X, et al. Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem 2005; 280:29728-42.
25. Ganter B, Fu S-l, Lipsick JS. D-type cyclins repress transcriptional activation by the v-Myb but not the c-Myb DNA-binding domain. EMBO J 1998; 17:255-68.
26. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, et al. Cyclin D1 Binds the Androgen Receptor and Regulates Hormone-Dependent Signaling in a p300/CBP-Associated Factor (P/CAF)-Dependent Manner. Mol Endocrinol 2001; 15:797-811.
27. Neuman E, Ladha M, Lin N, Upton T, Miller S, DiRenzo J, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 1997; 17:5338-47. (Pubitemid 27357632)
28. Sarruf DA, Iankova I, Abella A, Assou S, Miard S, Fajas L. Cyclin D3 promotes adipogenesis through activation of Peroxisome Proliferator-Activated Receptor γ. Mol Cell Biol 2005; 25:9985-95. (Pubitemid 41572745)
29. Rao SS, Kohtz DS. Positive and negative regulation of D-type cyclin expression in skeletal myoblasts by basic fibroblast growth factor and transforming growth factor β. J Biol Chem 1995; 270:4093-100.
30. 1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 1998; 17:1027-37.
31. Peterson LF, Boyapati A, Ranganathan V, Iwama A, Tenen DG, Tsai S, Zhang D-E. The hematopoietic transcription factor AML1 (RUNX1) Is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol 2005; 25:10205-19. (Pubitemid 41681949)
32. Berger C, Pallavi SK, Prasad M, Shashidhara LS, Technau GM. A critical role for cyclin E in cell fate determination in the central nervous system of Drosophila melanogaster. Nat Cell Biol 2005; 7:56-62.
33. Berger C, Pallavi SK, Prasad M, Shashidhara LS, Technau GM, Berger C, et al. Cyclin E acts under the control of Hox-genes as a cell fate determinant in the developing central nervous system: A critical role for cyclin E in cell fate determination in the central nervous system of Drosophila melanogaster. Cell Cycle 2005; 4:422-5.
34. Cowan CR, Hyman AA. Cyclin E-Cdk2 temporally regulates centrosome assembly and establishment of polarity in Caenorhabditis elegans embryos. Nat Cell Biol 2006; 8:1441-7.
35. Skapek SX, Rhee J, Kim PS, Novitch BG, Lassar AB. Cyclin-mediated inhibition of muscle gene expression via a mechanism that is independent of pRb hyperphosphorylation. Mol Cell Biol 1996; 16:7043-53. (Pubitemid 26389763)
36. Gross I, Lhermitte B, Domon-Dell C, Duluc I, Martin E, Gaiddon C, et al. Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation. Oncogene 2005; 24:7955-63. (Pubitemid 41746739)
37. Zhang JM, Wei Q, Zhao X, Paterson BM. Coupling of the cell cycle and myogenesis through the cyclin D1-dependent interaction of MyoD with Cdk4. EMBO J 1999; 18:926-33. (Pubitemid 29082272)
38. Lazaro J-B, Bailey PJ, Lassar AB. Cyclin D-Cdk4 activity modulates the subnuclear localization and interaction of MEF2 with SRC-family coactivators during skeletal muscle differentiation. Genes Dev 2002; 16:1792-805.
39. Grossel MJ, Hinds PW. Beyond the cell cycle: A new role for Cdk6 in differentiation. J Cell Biochem 2006; 97:485-93.
40. Slomiany P, Baker T, Elliott E, Grossel M. Changes in motility, gene expression and actin dynamics: Cdk6-induced cytoskeletal changes associated with differentiation in mouse astrocytes. J Cell Biochem 2006; 99:635-46. (Pubitemid 44435579)
41. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005; 24:2776-86.
42. Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M, et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 2003; 12:381-92. (Pubitemid 37238925)
43. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18:2699-711.
44. Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8:1136-44.
45. Zhu H, Nie L, Maki CG. Cdk2-dependent inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem 2005; 280:29282-8. (Pubitemid 41161383)
46. Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells. J Biol Chem 2005; 280:18120-9.
47. Gui H, Li S, Matise MP. A cell-autonomous requirement for Cip/Kip cyclin-kinase inhibitors in regulating neuronal cell cycle exit but not differentiation in the developing spinal cord. Dev Biol 2007; 301:14-26. (Pubitemid 44958402)
48. Gartel AL. Inducer and inhibitor: "Antagonistic duality" of p21 in differentiation. Leukemia Res 2006; 30:1215-6.
49. WAF1 control of epithelial cell cycle and cell fate. Critical Reviews in Oral Biology and Medicine 2002; 13:453-64.
50. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, Dotto GP. Involvement of the cell cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 1995; 92:5451-5.
51. WAF1/CIP1 acts as a brake in osteoblast differentiation. J Bone Miner Res 2003; 18:818-26.
52. Waf1 inhibits granulocytic differentiation of 32Dcl3 cells. Leukemia Res 2006; 30:1285-92.
53. Cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep 2001; 2:27-34.
54. 1 cyclin-dependent kinases, uncouples differentiation and growth arrest during the granulosa->luteal transition. Cell Growth Differ 1998; 9:787-94.
55. Nguyen L, Besson A, Roberts JM, Guillemot F. Coupling cell cycle exit, neuronal differentiation and migration in cortical neurogenesis. Cell Cycle 2006; 5:2314-8. (Pubitemid 44785839)
56. Kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes and Development 2006; 20:1511-24.
57. Korenjak M, Brehm A. E2F-Rb complexes regulating transcription of genes important for differentiation and development. Curr Opin Genet Dev 2005; 15:520-7. (Pubitemid 41262408)
58. Goodrich DW. The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene 2006; 25:5233-43.
59. Lipinski MM, Jacks T. The retinoblastoma gene family in differentiation and development. Oncogene 1999; 18:7873-82. (Pubitemid 30066233)
60. Benevolenskaya EV, Murray HL, Branton P, Young RA, Kaelin JWG. Binding of pRb to the PHD protein RBP2 promotes cellular differentiation. Mol Cell 2005; 18:623-35. (Pubitemid 40804799)
61. Batsche E, Moschopoulos P, Desroches J, Bilodeau S, Drouin J. Retinoblastoma and the related pocket protein p107 act as coactivators of NeuroD1 to enhance gene transcription. J Biol Chem 2005; 280:16088-95.
62. Classon M, Kennedy BK, Mulloy R, Harlow E. Opposing roles of pRb and p107 in adipocyte differentiation. Proc Natl Acad Sci USA 2000; 97:10826-31.
63. Oakes S, Hilton H, Ormandy C. Key stages in mammary gland development - The alveolar switch: coordinating the proliferative cues and cell fate decisions that drive the formation of lobuloalveoli from ductal epithelium. Breast Cancer Res 2006; 8:207.
64. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 2009; 23:2563-77.
65. LaMarca HL, Rosen JM. Hormones and mammary cell fate - What will I become when I grow up? Endocrinology 2008; 149:4317-21.
66. Coletta RD, Jedlicka P, Gutierrez-Hartmann A, Ford HL. Transcriptional control of the cell cycle in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2004; 9:39-53.
67. Brisken C, Rajaram RD. Alveolar and lactogenic differentiation. J Mammary Gland Biol Neoplasia 2006; 11:239-48.
68. Jerry DJ, Kuperwasser C, Downing SR, Pinkas J, He C, Dickinson E, et al. Delayed involution of the mammary epithelium in BALB/c-p53 null mice. Oncogene 1998; 17:2305-12. (Pubitemid 28515383)
69. Kip1 is required for mouse mammary gland morphogenesis and function. J Cell Biol 2001; 153:917-32.
70. Hu G, Lee H, Price SM, Shen MM, Abate-Shen C. Msx homeobox genes inhibit differentiation through upregulation of cyclin D1. Development 2001; 128:2373-84. (Pubitemid 32633369)
71. Jiang Z, Zacksenhaus E. Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation and adenocarcinoma. J Cell Biol 2002; 156:185-98. (Pubitemid 34846946)
72. Fantl V, Edwards PA, Steel JH, Vonderhaar BK, Dickson C. Impaired mammary gland development in Cyl-1 (-/-) mice during pregnancy and lactation is epithelial cell autonomous. Dev Biol 1999; 212:1-11.
73. Sicinski P, Weinberg RA. A specific role for cyclin D1 in mammary gland development. J Mammary Gland Biol Neoplasia 1997; 2:335-42.
74. Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, et al. Stromal and epithelial Caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J Pathol 2006; 169:1784-801.
75. Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, et al. The cyclin D1 gene is transcriptionally repressed by Caveolin-1. J Biol Chem 2000; 275:21203-9.
76. Grimm SL, Rosen JM. The role of C/EBPβ in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003; 8:191-204.
77. Rosen JM. Striking it rich by data mining. Cell 2003; 114:271-2.
78. Sakamaki T, Casimiro MC, Ju X, Quong AA, Katiyar S, Liu M, et al. Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol 2006; 26:5449-69.
79. Zahnow CA, Younes P, Laucirica R, Rosen JM. Overexpression of C/EBPβ-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J Natl Cancer Inst 1997; 89:1887-91.
80. Seagroves TN, Krnacik S, Raught B, Gay J, Burgess-Beusse B, Darlington GJ, Rosen JM. C/EBPβ, but not C/EBPα, is essential for ductal morphogenesis, lobuloalveolar proliferation and functional differentiation in the mouse mammary gland. Genes Dev 1998; 12:1917-28.
81. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998; 1:465-70.
82. Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV, et al. Differential expression of the Peroxisome Proliferator-Activated Receptor γ (PPARγ) and its coactivators Steroid Receptor Coactivator-1 and PPAR-binding protein (PBP) in the brown fat, urinary bladder, colon and breast of the mouse. Am J Pathol 1998; 153:349-54.
83. 0 growth arrest and apoptosis. J Biol Chem 1999; 274:16582-9.
84. Wang C, Fu M, D'Amico M, Albanese C, Zhou J-N, Brownlee M, et al. Inhibition of cellular proliferation through IκB kinase-independent and Peroxisome Proliferator-Activated Receptor γ-dependent repression of cyclin D1. Mol Cell Biol 2001; 21:3057-70. (Pubitemid 32298373)
85. Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 2001; 286:916-22. (Pubitemid 32924859)
86. Suzuki T, Hayashi S, Miki Y, Nakamura Y, Moriya T, Sugawara A, et al. Peroxisome Proliferator-Activated Receptor γ in human breast carcinoma: a modulator of estrogenic actions. Endocr Relat Cancer 2006; 13:233-50.
87. Yang Q, Kurotani R, Yamada A, Kimura S, Gonzalez FJ. Peroxisome Proliferator-Activated Receptor a activation during pregnancy severely impairs mammary lobuloalveolar development in mice. Endocrinology 2006; 147:4772-80. (Pubitemid 44402184)
88. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002; 111:29-40.
89. INK4A Is critical for growth arrest during mammary involution. Cancer Res 2001; 61:8811-9.
90. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369:669-71. (Pubitemid 24199473)
91. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006; 9:13-22. (Pubitemid 43069507)
92. Robinson GW, Wagner KU, Hennighausen L. Functional mammary gland development and oncogene-induced tumor formation are not affected by the absence of the retinoblastoma gene. Oncogene 2001; 20:7115-9. (Pubitemid 33052205)
93. Francis SM, Bergsied J, Isaac CE, Coschi CH, Martens AL, Hojilla CV, et al. A functional connection between pRb and Transforming Growth Factor β in growth inhibition and mammary gland development. Mol Cell Biol 2009; 29:4455-66.
94. WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor α. Mol Cell Biol 2005; 25:2419-30.
95. 1 checkpoint control. Cell 1995; 82:675-84.
96. Kip1 regulates both DNA synthesis and apoptosis in mammary epithelium but is not required for its functional development during pregnancy. Mol Endocrinol 2003; 17:2436-47.
97. Said TK, Moraes RCB, Singh U, Kittrell FS, Medina D. Cyclin-dependent kinase (CDK) inhibitors/Cdk4/Cdk2 complexes in early stages of mouse mammary preneoplasia. Cell Growth Differ 2001; 12:285-95. (Pubitemid 32678220)
98. Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad Sci USA 2001; 98:194-9.
99. Caldon CE, Swarbrick A, Lee CS, Sutherland RL, Musgrove EA. The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Res 2008; 68:3026-36. (Pubitemid 351556304)
100. Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, et al. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 1999; 97:767-77.
101. Das G, Choi Y, Sicinski P, Levine E. Cyclin D1 finetunes the neurogenic output of embryonic retinal progenitor cells. Neural Dev 2009; 4:15.
102. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16:1723-39.
103. van Diest PJ, van der Wall E, Baak JPA. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004; 57:675-81.
104. Mommers ECM, Leonhart AM, Falix F, Michalides R, Meijer CJLM, Baak JPA, van Diest PJ. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. The Journal of Pathology 2001; 194:327-33. (Pubitemid 32624559)
105. Lacroix M, Toillon R-A, Leclercq G. Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 2004; 11:497-522.
106. Loden M, Stighall M, Nielsen NH, Roos G, Emdin SO, Ostlund H, Landberg G. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 2002; 21:4680-90. (Pubitemid 34833145)
107. Kenny FS, Hui R, Musgrove EA, Gee JMW, Blamey RW, Nicholson RI, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999; 5:2069-76. (Pubitemid 29399260)
108. Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, et al. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 2004; 25:375-80. (Pubitemid 38344404)
109. Rudolph P, Kühling H, Alm P, Fernö M, Baldetorp B, Olsson H, Parwaresch R. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 2003; 105:674-80. (Pubitemid 36687736)
110. Nielsen NH, Loden M, Cajander J, Emdin SO, Landberg G. G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res Treat 1999; 56:105-12. (Pubitemid 29494828)
111. Spyratos F, Andrieu C, Vidaud D, Briffod M, Vidaud M, Lidereau R, Bieche I. CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer. Int J Biol Markers 2000; 15:210-4.
112. 1 cyclin expression in breast cancer cells. Oncogene 1998; 16:2865-78.
113. Zwicker J, Brusselbach S, Jooss KU, Sewing A, Behn M, Lucibello FC, Muller R. Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation. Oncogene 1999; 18:19-25. (Pubitemid 29060575)
114. Carthon BC, Neumann CA, Das M, Pawlyk B, Li T, Geng Y, Sicinski P. Genetic replacement of cyclin D1 function in mouse development by cyclin D2. Mol Cell Biol 2005; 25:1081-8. (Pubitemid 40165814)
115. Pirkmaier A, Dow R, Ganiatsas S, Waring P, Warren K, Thompson A, et al. Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma. Oncogene 2003; 22:4425-33.
116. Bartkova J, Zemanova M, Bartek J. Abundance and subcellular localisation of cyclin D3 in human tumours. Int J Cancer 1996; 65:323-7. (Pubitemid 26059986)
117. Wong SCC, Chan JKC, Lee KC, Hsiao WLW. Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Pathol 2001; 194:35-42.
118. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002; 110:633-41.
119. Alkarain A, Jordan R, Slingerland J. p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 2004; 9:67-80. (Pubitemid 39137497)
120. Waf1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with longterm follow-up. Clin Cancer Res 1996; 2:1591-9.
121. Waf1 correlates with DNA replication but not with prognosis in invasive breast cancer. J Clin Pathol 2001; 54:866-70.
122. WAF1/CIP1 expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat 2000; 61:33-43.
123. + immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 2009; 33:163-75.
124. Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew K, Moore D, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007; 12:479-91.
125. Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle 2007; 6:667-71.
126. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006; 6:99-106.
127. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98:262-72.
128. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65:4059-66.
129. Yang C, Trent S, Ionescu-Tiba V, Lan L, Shioda T, Sgroi D, Schmidt EV. Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res 2006; 66:11649-58.
130. Harris H. Tumour suppression: Putting on the brakes. Nature 2004; 427:201.
131. Gocek E, Studzinski GP. Vitamin D and differentiation in cancer. Critical Reviews in Clinical Laboratory Sciences 2009; 46:190-209.
132. Su Y, Vanderlaag K, Ireland C, Ortiz J, Grage H, Safe S, Frankel A. 1,1-Bis(3′-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice. Breast Cancer Res 2007; 9:56.
133. Kopelovich L, Fay JR, Glazer RI, Crowell JA. Peroxisome Proliferator-Activated Receptor modulators as potential chemopreventive agents. Mol Cancer Ther 2002; 1:357-63.
134. Yin Y, Russell RG, Dettin LE, Bai R, Wei Z-L, Kozikowski AP, et al. Peroxisome Proliferator-Activated Receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 2005; 65:3950-7.
135. Fenner MH, Elstner E. Peroxisome Proliferator-Activated Receptor γ ligands for the treatment of breast cancer. Expert Opin Investig Drugs 2005; 14:557-68. (Pubitemid 40895186)
136. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR)gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003; 79:391-7. (Pubitemid 36750946)
137. Yee LD, Williams N, Wen P, Young DC, Lester J, Johnson MV, et al. Pilot study of Rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 2007; 13:246-52. (Pubitemid 46121876)
138. 3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 1998; 142:57-65.
139. Colston K, Hansen C. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002; 9:45-59. (Pubitemid 34298363)
140. Campbell MJ, Adorini L. The vitamin D receptor as a therapeutic target. Expert Opinion on Therapeutic Targets 2006; 10:735-48.
141. 3 resistance in mammary cells. J Steroid Biochem Mol Biol 2007; 103:703-7.
142. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood 2009; 113:3655-65.
143. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181-93. (Pubitemid 33741893)
144. Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AMH, et al. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer 2007; 96:1204-15.
145. Boyle JO, Langenfeld J, Lonardo F, Sekula D, Reczek P, Rusch V, et al. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized and transformed human bronchial epithelial cells. J Natl Cancer Inst 1999; 91:373-9. (Pubitemid 29102338)
146. Dow R, Hendley J, Pirkmaier A, Musgrove EA, Germain D. Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2. J Biol Chem 2001; 276:45945-51.
147. Yu Z, Lim W, Lu Q, Wang L, Zhang X, Han P, et al. p21 is required for atRA-mediated growth inhibition of MEPM cells, which involves RAR. J Cell Biochem 2008; 104:2185-92.
148. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003; 22:7305-15. (Pubitemid 37487162)
149. 1-phase arrest and differentiation in vitro. Exp Cell Res 1999; 249:70-85.
150. WAF1/CIP1. Oncogene 2005; 25:2304-17.
151. Wainwright LJ, Lasorella A, Iavarone A. Distinct mechanisms of cell cycle arrest control the decision between differentiation and senescence in human neuroblastoma cells. Proc Natl Acad Sci USA 2001; 98:9396-400. (Pubitemid 32743928)
152. Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009; 11:205.
153. Said TK, Medina D. Cell cycle genes in a mouse mammary hyperplasia model. J Mammary Gland Biol Neoplasia 2004; 9:81-93.
154. Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat 2009; 115:651-9.
155. Alle KM, Henshall SM, Field AS, Sutherland RL. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998; 4:847-54.